STUDresearch · Peptide
Davunetide (NAP)
Also known as
NAP · NAPVSIPQ · davunetide peptide
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Systemic
Intranasal
Cognitive / nootropic peptides
Systemic CNS-directed investigational NAP octapeptide delivered by metered intranasal spray in human trials; not a Khavinson bioregulator.
What people say
People ask about Davunetide for neuroprotection, attention and brain fog. Also called NAP or NAPVSIPQ, it is an ADNP-derived octapeptide developed as an intranasal CNS drug candidate, not a Khavinson bioregulator. MCI and PSP trials did not establish a primary clinical benefit.
Doses people talk about
Rows preserve per-administration amount, daily frequency, study population and duration. They describe historical trials and are not self-use instructions.
How it may feel
The inspected nootropic discussion asks about clarity and brain fog but supplies no direct Davunetide use account, so no typical day-one feel is established. Separately, nasal discomfort, runny nose and nosebleeds were more frequent in the 52-week PSP trial.
MCI lower arm5 mg intranasal once daily for 12 weeks
One randomized MCI arm; primary composite cognitive endpoint was not significant.
MCI higher arm15 mg intranasal twice daily for 12 weeks
Distinct MCI arm totaling 30 mg/day; it must not be compressed to 15 mg/day.
PSP arm30 mg intranasal twice daily for 52 weeks
Multicenter PSP trial totaling 60 mg/day; no benefit on either primary endpoint and more nasal adverse events.
Half-life & effect duration
- Half-life in the body
- Nasal · ratsAbout 71 minutes
- Felt duration people report
- Felt durationNo consistent Davunetide-specific firsthand window reported
Cycles people discuss
Older bioregulator-style talk mentions 10–20-day courses and seasonal short-on/long-off repeats; these are not established Davunetide schedules. Actual intranasal development used 12 weeks in MCI and 52 weeks in PSP, with four weeks of MCI follow-up—not a per-dose effect duration.
Timing
Human development programs used once- or twice-daily intranasal administration, depending on the trial arm. The retained record does not establish a preferred time of day or meal window, and those trial schedules do not supply an injectable routine.
Stacks
Davunetide is asked about beside Semax, Selank, Noopept and Dihexa, but the inspected thread did not supply a Davunetide stack experience. Adjacent-compound discussion should not be presented as an established combination.
Watch for
Tolerability claims and nasal adverse events: Vendor literature often claims generally mild effects and good tolerability; independent long-term data remain limited. In the 52-week PSP trial, epistaxis, rhinorrhea and nasal discomfort were more frequent with davunetide than placebo.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
A rat pharmacokinetic study reported a mean terminal plasma half-life of 70.7 minutes after intranasal NAP administration.
Adult male Sprague-Dawley rats had an intranasal plasma Tmax around 19 minutes and terminal half-life 70.7 ± 34.0 minutes; cerebrospinal-fluid Tmax was about 20–30 minutes.
Animal result reviewed from the publication abstract/metadata rather than full paper. It is route- and species-specific, cannot be treated as human PK, and does not establish clinical target engagement or felt duration.
- Pharmacokinetics of the neuroprotective peptide NAPVSIPQ in serial plasma and CSF samples after intravenous or intranasal administration (opens in a new tab)Publication abstract reports adult male Sprague-Dawley rat intranasal plasma terminal half-life 70.7 ± 34.0 minutes, plasma Tmax 19 ± 8.94 minutes, and CSF Tmax about 20–30 minutes; IV values were shorter.Only abstract/metadata content was available; animal route-specific values cannot establish human PK or clinical effect duration.
Felt duration people report
No measured or credible first-person Davunetide felt-duration window was established in the inspected sources.
Human studies report multi-week outcomes and nasal adverse events. The inspected community question named Davunetide, but later replies supplied experiences with other nootropics and one poster explicitly had not tried Davunetide.
Absence in one inspected thread and one secondary community scan is not proof that no account exists anywhere. Trial-course duration, nasal-event frequency and rat PK cannot be substituted for subjective human duration.
- Morimoto et al. — A double-blind, placebo-controlled, ascending-dose, randomized study of intranasal AL-108 for 12 weeks in mild cognitive impairment (opens in a new tab)Abstract describes a 144-subject, 12-week randomized intranasal AL-108 MCI study: primary composite memory endpoint was not significant, with individual-task signals and generally favorable tolerability.Abstract-level original trial report; individual-task signals are not a positive primary endpoint.
- Boxer et al. — Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial (opens in a new tab)313 participants across 48 centers received 30 mg intranasal davunetide twice daily or placebo for 52 weeks; neither primary endpoint improved. Epistaxis, rhinorrhea and nasal discomfort were more frequent on davunetide.PSP disease population and long-course outcome study; pharmacokinetics and target engagement were not measured and results do not define single-dose felt duration.
- Reddit r/Biohackers — Thoughts on Semax, Selank, Noopept, Davunetide and Dihexa (opens in a new tab)Original question names Davunetide; visible later replies discuss Semax, Selank or Noopept, and one commenter says they had tried all listed compounds apart from Dihexa and Davunetide. No first-person Davunetide account was found through the inspected follow-ups.One evolving thread is not an exhaustive community search; commenters, products and histories are unverified.
- Peptidings — NAP / Davunetide community evidence summary (opens in a new tab)Community section describes a near-empty first-person record and notes that alleged self-use protocols are commonly extrapolated from clinical doses rather than documented experience.Commercial secondary site, not primary research or an exhaustive forum archive; used only to bound community scarcity, not to validate efficacy or dosing.
Other context in this card
- Davunetide sex-dependently boosts memory in prodromal Alzheimer’s disease (opens in a new tab)Methods restate randomized arms of 5 mg once daily and 15 mg twice daily for 12 weeks plus four-week follow-up; analyses are post-hoc and sex-stratified.Retrospective reanalysis of an older trial, not a new confirmatory study; subgroup findings remain exploratory.
What people say
- Neuroprotection narrative and trial context: Community and regional literature frame NAP/ADNP benefits around neuroprotection and ‘normalization.’ In formal studies, intranasal davunetide was generally tolerated but missed the MCI composite cognitive endpoint and 52-week PSP primary endpoints; individual and post-hoc signals remain exploratory. forumtrial
- Focus / clarity talk: Davunetide (NAP) appears in questions about attention, mental fatigue and brain fog. The inspected Vyvanse/nootropic thread asked about these goals but supplied no direct Davunetide use report. forum
- Mood adjacency: Some logs mention motivation or anxiety edge changes — highly confounded by caffeine/sleep/stim stacks. anecdote
- Acute vs course discussion: General nasal/SC nootropic talk judges same-day experiences and uses multi-week courses for ‘is this real’ reassessment. That comparison does not establish a Davunetide effect window or SC regimen; its human programs assessed 12-week MCI and 52-week PSP intranasal treatment. forumtrial
- What exists: A 48-center, 52-week placebo-controlled PSP trial enrolled 313 participants and found no benefit on either primary endpoint. trial
Doses people talk about
- Not a standard research-chem SC chart. forum
- Route: intranasal in development programs. trial
- Historical intranasal clinical arms: MCI: 5 mg once daily or 15 mg twice daily for 12 weeks; PSP: 30 mg twice daily for 52 weeks. These are distinct trial arms, not one ~5–15 mg/day range. trial
- Framing: NAP/davunetide nasal clinical programs. trial
How it may feel
- Courses in older discussion: Bioregulator-style descriptions mention 10–20-day courses repeated a few times per year; this is not an established Davunetide schedule. Actual MCI and PSP programs assessed 12 and 52 weeks of intranasal treatment, respectively. forumtrial
- First-person gap: No direct Davunetide day-one experience was found in the inspected thread; replies covered Semax, Selank or Noopept instead. forum
- Days 2–7: Side-effect window for many agents; benefits, if any, are easy to mis-attribute. forum
- Weeks 1–2: First honest checkpoint in self-logs. forum
- During clinical use: Nasal discomfort, rhinorrhea and epistaxis—not injection-site or oral GI effects—were more frequent with davunetide in the 52-week PSP trial. trial
Cycles people discuss
- Course culture versus clinical use: Short-on, long-off, seasonal repeats appear in older bioregulator-style discussion, not established Davunetide schedules. Its human programs used continuous intranasal treatment for 12 weeks in MCI or 52 weeks in PSP. forumtrial
- Informal breaks versus study follow-up: Older self-protocol discussion describes weeks-on/weeks-off instead of indefinite daily use, driven more by cost and caution than hard science. That does not establish a Davunetide regimen. The MCI program's four-week follow-up was an observation window, not proof of persistent per-dose effects or a validated off-cycle. forumtrial
- No magic cycle: There is rarely one universal “correct” on/off calendar across forums. forum
- Reassess: Stop and reassess if adverse effects appear; this is not medical care. forum
Timing
- Timing practicalities: People time doses around side effects, training, and sleep more than perfect PK. Product-specific schedule context: Human development programs used once- or twice-daily intranasal administration, depending on the trial arm. The retained record does not establish a preferred time of day or meal window, and those trial schedules do not supply an injectable routine. forumtrial
- Acute-window comparison: General nasal/SC nootropic discussion uses hours as an evaluation window and notes sparse half-life data for analogs. This does not establish Davunetide felt duration or an SC schedule; its human trials report course outcomes and nasal adverse events, not a measured subjective window for one dose. forumtrial
- Species and route matter: A rat study reported intranasal NAP plasma terminal half-life of 70.7 ± 34.0 minutes; no product-specific human half-life was located. animal
More on what it is
- Evidence honesty: Much of the English-web discussion is secondary summaries and vendor literature; treat claims cautiously. forum
- Research posture: Educational summary of public discussion and literature themes only. forum
- How people talk about it: Forum volume is a popularity signal for Davunetide (NAP), not proof it works for you. forum
- What it is: Davunetide (NAP; NAPVSIPQ) is an ADNP-derived eight-amino-acid investigational neuroprotective peptide developed for intranasal CNS delivery; it is not a Khavinson/cytomedine bioregulator. trial
- Research only: Not approved advice for self-experimentation; legality and access vary by place. forum
Stacks
- Bioregulator marketing versus adjacent nootropics: Older organ-system protocols group multiple bioregulators, but Davunetide is not a Khavinson/cytomedine bioregulator. In the inspected discussion it appears beside Semax, Selank, Noopept and Dihexa in questions, without a first-person Davunetide stack account. forum
- Less is clearer: Solo runs make personal n=1 easier to interpret than five-compound blasts. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Tolerability claims and nasal adverse events: Vendor literature often claims generally mild effects and good tolerability; independent long-term data remain limited. In the 52-week PSP trial, epistaxis, rhinorrhea and nasal discomfort were more frequent with davunetide than placebo. forumtrial
- Allergy / unknown impurities: Gray-market risk. forum
- Injection site (if injected): Redness, itch, lumps, bruise — technique and product quality matter. forum
- Unknowns: Long-term safety for gray-market preparations is often poorly characterized. forum
- Stack noise: Sides logged on multi-agent stacks cannot be blamed cleanly on one compound. forum
- Seek care red flags: Severe allergic reaction, chest pain, neuro changes, or uncontrolled BP/glucose need real medical care — not forum advice. forum
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.